Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring

OBJECTIVE: The adalimumab biosimilars FKB327 and GP2017 were approved for the therapy of patients with inflammatory bowel disease (IBD). Relatively few prospective studies with biosimilar adalimumab in patients with IBD have been published. The aim of this prospective observational study was to eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasserbauer, Martin, Hlava, Stepan, Drabek, Jiri, Stovicek, Jan, Minarikova, Petra, Nedbalova, Lenka, Drasar, Tomas, Zadorova, Zdena, Dolina, Jiri, Konecny, Stefan, Kojecky, Vladimír, Kozeluhova, Jana, Cernikova, Pavlina, Pichlerova, Dita, Kucerova, Barbora, Coufal, Stepan, Keil, Radan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359532/
https://www.ncbi.nlm.nih.gov/pubmed/35939424
http://dx.doi.org/10.1371/journal.pone.0271299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359532/
https://www.ncbi.nlm.nih.gov/pubmed/35939424
http://dx.doi.org/10.1371/journal.pone.0271299

Ejemplares similares